A method of treating a mammal, comprising administering a therapeutically effective amount of a poly-oxygenated metal hydroxide composition to a mammal to reduce a proliferation of hypoxic carcinoma cells, wherein the poly-oxygenated metal hydroxide composition comprises a clathrate containing free oxygen gas (O.sub.2) molecules. The carcinoma cells may comprise lung carcinoma (A549). The poly-oxygenated metal hydroxide material is configured to provide bioavailable oxygen gas molecules to a mammal when administered to the mammal. The poly-oxygenated metal hydroxide composition can be administered intravenously, directly to carcinoma cells, and orally. The composition may comprise a fluid, where the poly-oxygenated metal hydroxide composition is soluble in the fluid.

A composition of chlorine-free poly-oxygenated metal hydroxide that comprises a clathrate containing oxygen gas molecules, and which may comprise a nutraceutical. In one embodiment, the poly-oxygenated metal hydroxide composition is soluble, and may have particles having a diameter of 212 m or less. The poly-oxygenated metal hydroxide may comprise of a poly-oxygenated aluminum hydroxide. The nutraceutical may include one or more of a protein, vitamin, fiber, mineral and electrolytes. The composition may be in a powder or fluid form, where the poly-oxygenated aluminum hydroxide is soluble in the fluid.

Methods and compositions for treating and/or preventing aging-related conditions are described. The compositions used in the methods include blood plasma and blood plasma fractions derived from blood plasma with efficacy in treating and/or preventing aging-related conditions such as cognitive disorders. The methods relate to a regimen of pulsed dosing of blood plasma or blood plasma fractions.

Activation of senescent stem cells in humans to promote wound healing and other therapies, and to promote general enhancement of health by application of non-thermal atmospheric pressure plasma (NTAPP) to tissues and body fluids such as blood. In particular, the targets of the NTAPP are stem cells. The products contained in NTAPP can affect the behavior of peripheral blood stem cells (PBSC) in blood, as well as stem cells found in tissues surrounding the blood in which said products are carried.

A method of treating a mammal, comprising administering a therapeutically effective amount of a poly-oxygenated metal hydroxide composition to a mammal to reduce a proliferation of hypoxic carcinoma cells, wherein the poly-oxygenated metal hydroxide composition comprises a clathrate containing free oxygen gas (O.sub.2) molecules. The carcinoma cells may comprise lung carcinoma (A549). The poly-oxygenated metal hydroxide material is configured to provide bioavailable oxygen gas molecules to a mammal when administered to the mammal. The poly-oxygenated metal hydroxide composition can be administered intravenously, directly to carcinoma cells, and orally. The composition may comprise a fluid, where the poly-oxygenated metal hydroxide composition is soluble in the fluid.

A composition of chlorine-free poly-oxygenated metal hydroxide that comprises a clathrate containing oxygen gas molecules, and which may comprise a nutraceutical. In one embodiment, the poly-oxygenated metal hydroxide composition is soluble, and may have particles having a diameter of 212 m or less. The poly-oxygenated metal hydroxide may comprise of a poly-oxygenated aluminum hydroxide. The nutraceutical may include one or more of a protein, vitamin, fiber, mineral and electrolytes. The composition may be in a powder or fluid form, where the poly-oxygenated aluminum hydroxide is soluble in the fluid.

A PN composition for treating multiple organ dysfunction syndrome (MODS) comprises a lipophilic or hydrophobic component, an amphiphilic emulsifier, a polar liquid carrier, and one or more electrolytes, where the amphiphilic emulsifier forms micelles having a lipophilic or hydrophobic core comprising the lipophilic or hydrophobic component in the polar liquid carrier, and/or liposomes organized as a lipid bilayer and/or other particle configurations. This is a PN composition that takes up nitric oxide and releases it with enhanced rapidity enabling it to shift the balance of nitric oxide from one that exacerbates organ damage and decreased survivability to one that reverses and/or inhibits organ damage and increases survivability.

The invention relates to the field of medicine and veterinary science, in particular to a perfluororganic compound-based gas transmission emulsion. A gas transmission emulsion that comprises a perfluororganic compound, a poloxamer and at least one additional excipient, wherein it comprises perfluoromethylcyclohexylpiperidine washed off of alcohol-soluble and water-soluble organic compounds as a perfluororganic compound and comprises poloxamer-188 as a poloxamer and is intended for intravenous administration to the subject. Thus, a PFOC-based gas transmission emulsion is created, the qualitative composition of which ensures the achievement of the technical result consisting in substantially reducing reactogenicity of the emulsion and making it possible to administer it to the subject.

The present disclosure provides stabilized hemoglobin compositions, uses thereof, and devices for administration thereof. The stabilized hemoglobin compositions may be useful in the treatment of various anemic or traumatic conditions involving inadequate blood or oxygen supply.

A method of treating a mammal, comprising administering a therapeutically effective amount of a poly-oxygenated metal hydroxide composition to a mammal to reduce a proliferation of hypoxic carcinoma cells, wherein the poly-oxygenated metal hydroxide composition comprises a clathrate containing free oxygen gas (O.sub.2) molecules. The carcinoma cells may comprise prostrate carcinoma (22Rv1). The poly-oxygenated metal hydroxide material is configured to provide bioavailable oxygen gas molecules to a mammal when administered to the mammal. The poly-oxygenated metal hydroxide composition can be administered intravenously, directly to carcinoma cells, and orally. The composition may comprise a fluid, where the poly-oxygenated metal hydroxide composition is soluble in the fluid.